Regulatory and Market Updates
What has changed in compounding rules, enforcement and pricing, and what to verify yourself.
What has changed in compounding rules, enforcement and pricing, and what to verify yourself.
Every page in this section states what we could verify and what we could not. Where a programme publishes nothing, that absence is recorded rather than filled in.
For context: across 32 tracked tirzepatide telehealth programmes, 17 publish a price we could capture, and the cheapest verified all-in cost is $215 a month at a 10 mg maintenance dose — about $2,580 for a first year. Compounded preparations are not FDA-approved. Prices captured 2026-08-05.
First-year all-in cost
Every page in this section
FDA Warning Letters to Compounded GLP-1 Marketers
What the letters actually cite, and how to search them yourself.
Tirzepatide Shortage Status
The designation that governs how much compounding is lawful.
503A Tirzepatide Rules
Patient-specific compounding, and its limits.
503B Tirzepatide Rules
Outsourcing facilities and federal oversight.
FDA 503B Bulks List Proposal
A proposal, not a final rule, and what it would change.
Telehealth Marketing Rules
The claims regulators have acted on.
FTC Weight-Loss Advertising Rules
Substantiation, testimonials and what a compliant page looks like.
Counterfeit Tirzepatide
Falsified product, research-labelled peptide, and why neither is detectable by eye.
Provider Price and Availability Changes
What moved since our last capture.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.